JAK inhibitor approval for vitiligo is not at all off topic. It’s very very much on topic. Vitiligo is the biggest market opportunity for RECELL by a long way and JAK inhibitors result in more stable vitiligo patients and increase the market for RECELL.
It is a match made “in heaven”
It is coming soon.
Truth be told I had a patient today who happened to have vitiligo and I mentioned to him a cure was on the near horizon and he was incredibly interested - which surprised me a little as his lesions didn’t seem too bad to me. This is set to generate a lot of noise when it drops.
An Article from TheStreet, page-6
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.82 |
Change
0.140(3.80%) |
Mkt cap ! $266.9M | |||
| Open | High | Low | Value | Volume |
| $3.83 | $3.87 | $3.77 | $1.433M | 374.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3987 | $3.82 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.86 | 200 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| AVH (ASX) Chart |